Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int J Neurosci 2016;126:20-24 | USF Parkinson's Disease and Movement Disorders Center

Kumar, R, RA Hauser, J Mostillo, N Dronamraju, A Graf, M Merschemke, and C Kenney. 2016. “Mavoglurant (AFQ056) in Combination With Increased Levodopa Dosages in Parkinson’s Disease Patients. Int J Neurosci 2016;126:20-24”. Int J Neurosci.

Last updated on 10/02/2024